(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/199455 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) *A61K 31/7125* (2006.01)
A61K 31/7115 (2006.01) *A61K 31/713* (2006.01)
A61K 31/712 (2006.01)

(21) International Application Number:
PCT/US2025/020936

(22) International Filing Date:
21 March 2025 (21.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/568,529 22 March 2024 (22.03.2024) US
63/762,453 24 February 2025 (24.02.2025) US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.** [US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **BONDURANT, Lucas**; c/o Alnylam Pharmaceuticals, Inc., 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142 (US). **MCININCH, James D.**; c/o Alnylam Pharmaceuticals, Inc., 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142 (US). **SCHLEGEL, Mark K.**; c/o Alnylam Pharmaceuticals, Inc., 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142 (US). **CASTORENO, Adam**; c/o Alnylam Pharmaceuticals, Inc., 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142 (US). **NGUYEN, Tuyen M.**; c/o Alnylam Pharmaceuticals, Inc., 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142 (US).

(74) Agent: **MEIGS, Julie Broadus** et al.; Womble Bond Dickinson (US) LLP, PO Box 570489, Atlanta, Georgia 30357-0037 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2025/199455 A1

(54) Title: IRNA COMPOSITIONS AND METHODS FOR SILENCING GROWTH FACTOR RECEPTOR BOUND PROTEIN 14 (GRB14) IN THE LIVER

(57) Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the GRB14 gene, as well as methods of inhibiting expression of GRB14, and methods of treating subjects that would benefit from reduction in expression of GRB14, such as subjects having a GRB14-associated disease, disorder, or condition, such as diabetes, using such dsRNA compositions.